NeurologyLive® Friday 5 — December 15, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Stigma in Epilepsy in 2023: How Far Have We Come?

In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.

2: IJMSC Insights: Drs Rainka, Aladeen, and Mattle on Medical Cannabis and MS

A new feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

3: NeuroVoices: Irfan Qureshi, MD, on the Therapeutic Potential of Antiseizure Agent BHV-7000

In this edition of NeuroVoices, the chief medical officer of Biohaven discussed early-stage data supporting the efficacy and safety of BHV-7000, a selective Kv7.2/7.3 potassium channel activator in development for patients with epilepsy.

4: Gaining Greater Insights Into Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders: Elizabeth M. Cassidy, MPH

The research project manager at the TSC Alliance provided additional clarity into a new study presented at AES 2023 assessing the links between TSC-associated neuropsychiatric disorders and seizure duration. [WATCH TIME: 4 minutes]

5: Growing Trofinetide’s Long-Term Profile as First Approved Rett Syndrome Therapy: Ponni Subbiah, MD, MPH

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, provided an overview of LILAC-2, a long-term, open-label study assessing the treatment benefits of trofinetide (Daybue). [WATCH TIME: 6 minutes]